FATE

Fate Therapeutics, Inc. - Common Stock (FATE)

About Fate Therapeutics, Inc. - Common Stock (FATE)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Details

Daily high

$2.58

Daily low

$2.44

Price at open

$2.52

52 Week High

$3.23

52 Week Low

$0.94

Market cap

303.1M

Dividend yield

Volume

4,484

Avg. volume

1.4M

P/E ratio

-2.40

Fate Therapeutics, Inc. - Common Stock News